Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bayer looking for a "mid-size M&A transaction" in oncology

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 18, 2023 11:05am

132 Views

Post# 35546001

RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

ONCY's late-stage phase 3 bio-platform technology in pelareorep addresses multiple unmet medical needs in the sought after oncology market space and is fairly valued for a M&A deal at between US$10 Billion to US$15 Billion.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing